A 27-year-old male experienced rapid hair loss after dengue fever, which activated a balding gene. The doctor suggested platelet-rich plasma treatment for hair regrowth.
The conversation discusses Melatonin's potential benefits for AGA and a product called "Asatex" by ASATONA AG. The company was uncooperative when contacted for purchase inquiries.
User discusses group buy for finerenone, a third-gen mineralocorticoid antagonist for hair loss treatment. Finerenone inhibits TGFb, NOX, and ROS, and improves renal and cardiac function; topical dose should be no more than 10mg per day.
A new topical treatment, PP405, shows promising results for hair regrowth, potentially outperforming existing treatments like finasteride and minoxidil. However, it may still need to be combined with DHT blockers for optimal results, and its long-term effectiveness remains uncertain.
People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.
A user experienced increased hair density loss after 4 months on dutasteride combined with finasteride. They are also using topical dutasteride with azelaic acid and alfatradiol but cannot tolerate antiandrogens like RU58841 due to headaches.
The conversation discusses using a violet ray device for hair regrowth, citing a case where zinc ion treatments showed promising results. It also mentions similar devices like the Growcombr and niostem helmet.
Scube3, a potential hair loss treatment, is unlikely to be released because it was given to a startup company, Amplifica, which may go bankrupt and fail to bring the treatment to market. Amplifica is prioritizing other treatments over Scube3, which could lead to financial loss and the end of Scube3's development.
PP405 shows promise as a hair loss treatment, with 31% experiencing increased hair density in a short trial. It may complement treatments like finasteride and minoxidil, but long-term effectiveness and safety need confirmation.
Clascoterone 5% solution showed a 539% improvement in hair count compared to placebo, but the actual increase in hair growth is minimal. Users express skepticism about the effectiveness of hair loss treatments.
Clascoterone phase 3 results show promising improvements in hair count, but concerns about high costs and lack of detailed data remain. Users compare it to existing treatments like Minoxidil and Finasteride, expressing skepticism about its accessibility and effectiveness.
The conversation is about the potential risk of permanent hair loss from PRP (platelet rich plasma) treatments and whether PRF (platelet rich fibrin) carries the same risk. The user is seeking information on this topic.
The conversation discusses using GHK Cu + AHK Cu peptides combined with topical dutasteride and minoxidil for hair regrowth. It mentions negative side effects of finasteride and promotes a specific copper peptide serum.
Scientists discovered a sugar gel, 2dDR-SA, that increased hair growth in mice. Users discussed its potential, comparing it to other treatments like Minoxidil and finasteride.
Yunce Medical, a Chinese company, is developing hair multiplication technology similar to Stemson Therapeutics, with potential for quicker availability due to favorable regulations. Users express skepticism and hope for future advancements in hair loss treatments.
The conversation is about the potential of SCUBE3 to regrow a juvenile hairline. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
The user experienced increased hair shedding after switching from finasteride to dutasteride, despite lifestyle improvements and additional treatments like oral minoxidil and PRP. They are concerned about persistent shedding, changes in hormone levels, and potential chronic telogen effluvium, and are considering a scalp biopsy for further investigation.
The conversation discusses biannual SCUBE3 injections and microneedling as treatments for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
PP405 is a potential new hair loss treatment that might replace finasteride and minoxidil, but it is still in clinical trials and may not be available until 2028-2031. There is skepticism about its effectiveness, with only a 20% increase in hair density observed in some participants.
The conversation discusses anticipation for CB-03-01, a potential new hair loss treatment that may be more effective and have a cleaner safety profile than finasteride. Users are hopeful but cautious, discussing current treatments like minoxidil, nizoral, and dermarolling, and the possibility of combining them with CB-03-01 for better results.
A user experiencing diffuse thinning at the hairline after 12 months on finasteride is considering adding minoxidil, dutasteride, or RU58841 to their treatment. Another user suggests adding minoxidil now, holding off on dutasteride, and shares personal side effects from RU58841.
A user is upset about hair loss due to seborrheic dermatitis and DUPA, which prevents a hair transplant. They mention using jojoba oil and discuss treatments like Minoxidil, finasteride, and RU58841.
A 21-year-old experiencing diffuse thinning is considering switching from finasteride to dutasteride after using topical and oral minoxidil and finasteride. They have seen some regrowth but are concerned about overall density loss, especially at the crown.
Creatine might speed up hair loss in those prone to male pattern baldness, possibly due to increased DHT levels. Some users experience no issues when using creatine with treatments like finasteride, minoxidil, or dutasteride.
A user is concerned about hair shedding despite noticeable regrowth after 7 months of using finasteride. The dermatologist confirmed positive results, but the user remains skeptical and confused.
The user has mostly recovered hair density using finasteride, alternating oral and topical minoxidil, and occasional dermarolling, but the crown area is still struggling. Advice includes continuing treatment for up to 24 months and possibly consulting a doctor if issues persist.
The user experienced a sudden decrease in hair density after starting alfatradiol while already using finasteride. Another user mentioned that initial shedding can occur with hair loss treatments, but it may not last long.
Considering alternative treatments to hair loss, such as platelet-rich plasma (PRP) and exosome therapy, instead of using medications like minoxidil, finasteride/dutasteride.